低分子肝素与普通肝素治疗不稳定型心绞痛的临床疗效观察

目的探讨低分子肝素与普通肝素治疗不稳定型心绞痛的近期疗效。方法将89例不稳定心绞痛患者随机分为低分子肝素组（46例,51.69%）和普通肝素组（43例,48.31%）,观察两组患者心绞痛发作次数、心电图的变化、急性心肌梗死、急性血管再通术和院内死亡发生率。结果与普通肝素组相比,低分子肝素组患者的心绞痛发作次数、心电图缺血、急性血管再通术的发生率明显降低,差异有统计学意义（P〈0.05）,两组均无严重出血。结论低分子肝素治疗不稳定型心绞痛疗效确切和安全。

Short-term efficacy observation of nadroparin calcium in patients with unstable angina

Objective To investigate the therapeutic efficacy of nadroparin calcium in patients with unstable angina.Methods 89 patients with unstable angina were randomized into 2 groups,nadroparin calcium group and control（heparin therapy） group.We observed the frequency of angina onset,ischemic changes in ECG,the incidences of myocardial infarction,emergent revascularization,and in-hospital mortality respectively after nadroparin calcium or Heparin therapy,and the outcomes were compared.Results The frequency of angina onset was decreased and myocardial ischemia was improved in nadroparin calcium group.There was a statistically significant difference（P〈0.05） comparing with control.There was no severe hemorrhagic complication in two groups.Conclusion The efficacy and safety of Nadroparin calcium therapy in patients with unstable angina was proved.